trending Market Intelligence /marketintelligence/en/news-insights/trending/oijaym9bnqdiqv96th7ylw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Lupin launches fungal infection tablets, oral suspension in US

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


Lupin launches fungal infection tablets, oral suspension in US

India's Lupin Ltd. announced the U.S. launch of Voriconazole to treat fungal infections in patients 12 years old and above.

The U.S.-FDA approved generic was launched in 50 mg and 200 mg tablets and 40 mg/ml oral suspension. Voriconazole will compete with PF Prism CV's Vfend tablets, which had U.S. sales of $81 million in the 12 months ended September and Vfend oral suspension which also generated $15.2 million during the same period.